This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
GoHealth 과거 순이익 실적
과거 기준 점검 0/6
GoHealth 의 수입은 연평균 -7.3%의 비율로 감소해 온 반면, Insurance 산업은 연평균 14.7%의 비율로 증가했습니다. 매출은 연평균 14.7%의 비율로 감소해 왔습니다.
핵심 정보
-7.29%
순이익 성장률
7.54%
주당순이익(EPS) 성장률
| Insurance 산업 성장률 | 8.02% |
| 매출 성장률 | -14.69% |
| 자기자본이익률 | n/a |
| 순이익률 | -192.35% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Jul 17
GOCO.Q: Chapter 11 Restructuring Will Drive Future Upside After Nasdaq Delisting
Analysts have reduced their fair value estimate for GoHealth from $5.13 to $2.75 per share, citing updated assumptions around revenue growth, profitability, and a lower projected future P/E multiple. What’s in the News for GoHealth GoHealth and several affiliates filed voluntary petitions for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 7, 2026, with reported assets in the range of US$500 million to US$1b and liabilities in the range of US$1b to US$10b (Bankruptcy Filing).내러티브 업데이트 • Jun 15
GOCO: Chapter 11 Reorganization Will Drive Future Upside Despite Imminent Delisting
Analysts have trimmed their price targets on GoHealth, citing slightly softer revenue growth assumptions and revised P/E outlooks following a recent downgrade highlighted in Street research. What's in the News GoHealth and certain subsidiaries filed voluntary Chapter 11 petitions in the US Bankruptcy Court for the District of Delaware on June 7, 2026, seeking reorganization with listed assets of $500 million to $1 billion and liabilities of $1 billion to $10 billion, according to court filings.내러티브 업데이트 • Jun 01
GOCO: Higher Growth Assumptions Will Support Upside Despite Nasdaq Listing Risk
Analysts have adjusted their price target on GoHealth from $4.70 to $5.13, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E following recent research, including a downgrade at Freedom Broker. What's in the News GoHealth reported that it will be unable to file its next 10-Q with the SEC by the required deadline, citing a delayed SEC filing as of May 18, 2026.
내러티브 업데이트 • Apr 30
GOCO: Lower P E And Improved Revenue Outlook Will Support Returns
Analysts have cut their 12 month price target for GoHealth by about $3, reflecting a reset in fair value assumptions along with updated views on revenue growth, margins and future P/E, following a recent downgrade highlighted in Street research. Analyst Commentary Bearish analysts are framing the latest downgrade as part of a broader reset in expectations for GoHealth, with the lower 12 month price target seen as a response to questions about how quickly the business can translate its model into consistent, scalable earnings.내러티브 업데이트 • Apr 14
GOCO: Lower Earnings Multiple Will Support Upside Despite Nasdaq Compliance Risk
Analysts cut their GoHealth price target from $7.70 to $4.70 as they factor in updated assumptions for revenue growth and margins, and incorporate the recent downgrade at Freedom Broker into their outlook. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$4.70 target as a cleaner entry point that better reflects current expectations for revenue growth and margins, which they see as more achievable under updated assumptions.내러티브 업데이트 • Mar 31
GOCO: Discount Rate Tweaks Will Support Upside Despite Nasdaq Compliance Risk
Analysts have nudged up their price target on GoHealth to $7.70, citing a slightly lower discount rate and modest tweaks to long term revenue growth, profit margin, and future P/E assumptions as key drivers of the change. What's in the News On March 18, 2026, GoHealth received a notice from Nasdaq that it is not in compliance with the minimum US$35 million market value of listed securities requirement under Listing Rule 5550(b)(2) (Nasdaq filing).내러티브 업데이트 • Mar 17
GOCO: Stable Assumptions And Low Future P E Will Support Returns
Analysts have kept their GoHealth price target unchanged at $4.50. They point to only slight tweaks in revenue growth, profit margin and forward P/E assumptions that do not materially alter their overall view of the stock.내러티브 업데이트 • Mar 03
GOCO: Stronger Margins And Lower P E Will Support Future Cash Flow
Analysts have trimmed their price target on GoHealth to reflect slightly weaker revenue expectations, a modestly stronger profit margin, and a marginally lower forward P/E. This results in a small downward adjustment in their $ price outlook for the stock.내러티브 업데이트 • Feb 17
GOCO: Carrier Relationship Reset Will Support Future Cash Flow Recovery
Analysts have sharply reduced GoHealth's target, with one firm lowering its price target to $5 from $12 after Q3 results came in below expectations because of topline weakness tied to a suspended relationship with a large carrier. Analyst Commentary Bearish analysts are recalibrating their expectations after Q3 results came in well below what they were looking for, and the cut in the price target to $5 from $12 signals a more cautious stance on the stock.내러티브 업데이트 • Feb 03
GOCO: Cash Burn Discipline And Carrier Reset Could Support Future Upside
Analysts have cut their price targets on GoHealth, including a reduction to US$5 from US$12. They cited weaker than expected Q3 results tied to topline softness from a suspended carrier relationship, a pullback in new enrollment growth, and ongoing concerns about market headwinds and cash flow sustainability.내러티브 업데이트 • Jan 20
GOCO: Cash Discipline And Carrier Reset Will Support Future Cash Flow
Analysts have sharply reduced their GoHealth price targets, with one moving from US$12 to US$5. This reflects weaker Q3 results tied to a suspended carrier relationship, as well as concerns about ongoing market headwinds and cash flow visibility.내러티브 업데이트 • Jan 06
GOCO: Focus On Cash Burn Discipline And Carrier Reset Supporting Future Stability
Narrative Update on GoHealth Analysts have cut their 12 month price target for GoHealth to US$5.00 from US$12.00, reflecting weaker Q3 results tied to a suspended relationship with a large carrier, softer revenue and Medicare submissions, a pullback in new enrollment growth, and concerns around ongoing market headwinds and uncertainty about achieving sustainable positive cash flow. Analyst Commentary Recent research updates on GoHealth reflect a cautious reset of expectations following Q3 results that came in below prior estimates, with price targets and ratings adjusted to reflect execution risks and a more uncertain growth outlook.내러티브 업데이트 • Dec 15
GOCO: Cash Flow Improvements Will Outweigh Carrier Loss And Enrollment Pullback
Analysts have sharply reduced their price target on GoHealth from approximately $12.00 to about $5.00 per share. This reflects weaker than expected Q3 results, revenue headwinds from a suspended carrier relationship, and persistent concerns about the company's ability to deliver sustainable growth and cash flow in a challenging market.내러티브 업데이트 • Dec 01
GOCO: Focus On Profitability And Cash Burn Reduction Will Drive Future Stability
Analysts have sharply reduced GoHealth's fair value estimate from $14 to $7.70 per share. They cite ongoing market headwinds, weaker-than-expected Q3 results, and challenges in revenue growth as key reasons for the downward revision.내러티브 업데이트 • Nov 17
GOCO: Recent Credit Move Will Boost Flexibility Ahead of Enrollment Period
Analysts have revised GoHealth's fair value estimate downward from $17.20 to $14.00. This change is due to updated model assumptions and increased caution surrounding revenue growth following recent company results and financial transactions.내러티브 업데이트 • Aug 25
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
GoHealth’s price target has been revised downward to $18.40, primarily reflecting reduced expectations for both future earnings multiples and revenue growth. What's in the News GoHealth has formed a Transformation Committee with new board members to evaluate strategic opportunities, including acquisitions, securitizations, and capital structure options.내러티브 업데이트 • Aug 10
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
Despite higher revenue growth forecasts, GoHealth’s future P/E multiple has dropped sharply, indicating reduced investor confidence in earnings quality or sustainability, leading to a lower consensus price target of $19.60. What's in the News GoHealth has formed a Transformation Committee to evaluate acquisitions, financial structure options, securitizations, and other strategic opportunities for value creation.
새로운 내러티브 • Mar 31
Medicare Engagement And Efficiency Will Drive Future Savings
GoHealth's shift to Medicare engagement enhances consumer relations and boosts operational efficiency, lowering costs and improving margins.매출 및 비용 세부 내역
매출 및 비용 세부 내역
GoHealth가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 153 | -294 | 202 | 34 |
| 31 Dec 25 | 362 | -261 | 313 | 35 |
| 30 Sep 25 | 738 | -203 | 501 | 39 |
| 30 Jun 25 | 822 | -30 | 546 | 39 |
| 31 Mar 25 | 834 | -2 | 566 | 40 |
| 31 Dec 24 | 799 | -7 | 539 | 41 |
| 30 Sep 24 | 686 | -33 | 495 | 41 |
| 30 Jun 24 | 700 | -64 | 486 | 42 |
| 31 Mar 24 | 737 | -67 | 513 | 44 |
| 31 Dec 23 | 735 | -67 | 507 | 43 |
| 30 Sep 23 | 527 | -127 | 478 | 43 |
| 30 Jun 23 | 528 | -132 | 477 | 43 |
| 31 Mar 23 | 544 | -146 | 504 | 43 |
| 31 Dec 22 | 632 | -150 | 585 | 46 |
| 30 Sep 22 | 1,012 | -242 | 786 | 50 |
| 30 Jun 22 | 1,091 | -233 | 859 | 50 |
| 31 Mar 22 | 1,129 | -201 | 853 | 52 |
| 31 Dec 21 | 1,062 | -189 | 782 | 48 |
| 30 Sep 21 | 1,059 | 2 | 611 | 43 |
| 30 Jun 21 | 1,010 | -33 | 713 | 71 |
| 31 Mar 21 | 941 | -20 | 630 | 64 |
| 31 Dec 20 | 877 | -19 | 570 | 59 |
| 30 Sep 20 | 720 | -27 | 462 | 55 |
| 30 Jun 20 | 664 | 16 | 310 | 48 |
| 31 Mar 20 | 611 | 10 | 277 | 47 |
| 31 Dec 19 | 540 | 16 | 249 | 46 |
| 31 Dec 18 | 226 | 28 | 102 | 16 |
양질의 수익: GOCO.Q 은(는) 현재 수익성이 없습니다.
이익 마진 증가: GOCO.Q는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: GOCO.Q은 수익성이 없으며 지난 5년 동안 손실이 연평균 7.3% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 GOCO.Q의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: GOCO.Q은 수익성이 없어 지난 해 수익 성장률을 Insurance 업계(27.3%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: GOCO.Q의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/21 02:38 |
| 종가 | 2026/07/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
GoHealth, Inc.는 13명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Steven Valiquette | Barclays |
| Michael Cherny | BofA Global Research |
| Elizabeth Anderson | Evercore ISI |